Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function.

McIntosh AG, Parker DC, Egleston BL, Uzzo RG, Haseebuddin H, Joshi SS, Viterbo R, Greenberg RE, Chen DYT, Smaldone MC, Kutikov.

BJU Int. 2019 May 30. doi: 10.1111/bju.14839. [Epub ahead of print]

PMID:
31145523
2.

Interpretable Representation Learning for Healthcare via Capturing Disease Progression through Time.

Bai T, Egleston BL, Zhang S, Vucetic S.

KDD. 2018 Aug;2018:43-51. doi: 10.1145/3219819.3219904.

PMID:
31037221
3.

Common Pitfalls of Head and Neck Research Using Cancer Registries.

Jones EA, Shuman AG, Egleston BL, Liu JC.

Otolaryngol Head Neck Surg. 2019 Apr 2:194599819838823. doi: 10.1177/0194599819838823. [Epub ahead of print]

PMID:
30939098
4.

EHR phenotyping via jointly embedding medical concepts and words into a unified vector space.

Bai T, Chanda AK, Egleston BL, Vucetic S.

BMC Med Inform Decis Mak. 2018 Dec 12;18(Suppl 4):123. doi: 10.1186/s12911-018-0672-0.

5.

Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study.

Beri N, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR.

Clin Genet. 2019 Feb;95(2):293-301. doi: 10.1111/cge.13474. Epub 2018 Dec 7.

PMID:
30417332
6.

Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible.

Egleston BL, Pedraza O, Wong YN, Griffin CL, Ross EA, Beck JR.

Contemp Clin Trials Commun. 2018 Jan 31;9:135-142. doi: 10.1016/j.conctc.2018.01.004. eCollection 2018 Mar.

7.

Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.

Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS.

J Natl Cancer Inst. 2018 Sep 1;110(9):985-993. doi: 10.1093/jnci/djy015.

8.

Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.

Gordon RE, Zhang L, Peri S, Kuo YM, Du F, Egleston BL, Ng JMY, Andrews AJ, Astsaturov I, Curran T, Yang ZJ.

Clin Cancer Res. 2018 Mar 15;24(6):1375-1388. doi: 10.1158/1078-0432.CCR-17-2923. Epub 2018 Feb 6.

9.

Joint Learning of Representations of Medical Concepts and Words from EHR Data.

Bai T, Chanda AK, Egleston BL, Vucetic S.

Proceedings (IEEE Int Conf Bioinformatics Biomed). 2017 Nov;2017:764-769. doi: 10.1109/BIBM.2017.8217752. Epub 2017 Dec 18.

10.

On the Use of Summary Comorbidity Measures for Prognosis and Survival Treatment Effect Estimation.

Gilbert EA, Krafty RT, Bleicher RJ, Egleston BL.

Health Serv Outcomes Res Methodol. 2017 Dec;17(3-4):237-255. doi: 10.1007/s10742-017-0171-2. Epub 2017 Jun 21.

11.

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

Meeker CR, Wong YN, Egleston BL, Hall MJ, Plimack ER, Martin LP, von Mehren M, Lewis BR, Geynisman DM.

J Natl Compr Canc Netw. 2017 Oct;15(10):1224-1233. doi: 10.6004/jnccn.2017.0161.

PMID:
28982748
12.

Latent Class Survival Models Linked by Principal Stratification to Investigate Heterogenous Survival Subgroups Among Individuals With Early-Stage Kidney Cancer.

Egleston BL, Uzzo RG, Wong YN.

J Am Stat Assoc. 2017;112(518):534-546. doi: 10.1080/01621459.2016.1240078. Epub 2016 Oct 7.

13.

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Jung S, Allen N, Arslan AA, Baglietto L, Barricarte A, Brinton LA, Egleston BL, Falk RT, Fortner RT, Helzlsouer KJ, Gao Y, Idahl A, Kaaks R, Krogh V, Merritt MA, Lundin E, Onland-Moret NC, Rinaldi S, Schock H, Shu XO, Sluss PM, Staats PN, Sacerdote C, Travis RC, Tjønneland A, Trichopoulou A, Tworoger SS, Visvanathan K, Weiderpass E, Zeleniuch-Jacquotte A, Dorgan JF.

Int J Cancer. 2018 Jan 15;142(2):262-270. doi: 10.1002/ijc.31058. Epub 2017 Oct 4.

14.

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.

Fortner RT, Schock H, Jung S, Allen NE, Arslan AA, Brinton LA, Egleston BL, Falk RT, Gunter MJ, Helzlsouer KJ, Idahl A, Johnson TS, Kaaks R, Krogh V, Lundin E, Merritt MA, Navarro C, Onland-Moret NC, Palli D, Shu XO, Sluss PM, Staats PN, Trichopoulou A, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF.

Br J Cancer. 2017 Oct 24;117(9):1412-1418. doi: 10.1038/bjc.2017.299. Epub 2017 Sep 5.

15.

Policy Research Challenges in Comparing Care Models for Dual-Eligible Beneficiaries.

Van Cleave JH, Egleston BL, Brosch S, Wirth E, Lawson M, Sullivan-Marx EM, Naylor MD.

Policy Polit Nurs Pract. 2017 May;18(2):72-83. doi: 10.1177/1527154417721909. Epub 2017 Jul 24.

PMID:
28735567
16.

Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Jung S, Allen N, Arslan AA, Baglietto L, Brinton LA, Egleston BL, Falk R, Fortner RT, Helzlsouer KJ, Idahl A, Kaaks R, Lundin E, Merritt M, Onland-Moret C, Rinaldi S, Sánchez MJ, Sieri S, Schock H, Shu XO, Sluss PM, Staats PN, Travis RC, Tjønneland A, Trichopoulou A, Tworoger S, Visvanathan K, Krogh V, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF.

Fertil Steril. 2017 Apr;107(4):1012-1022.e2. doi: 10.1016/j.fertnstert.2017.02.105.

17.

Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy.

Waingankar N, Mallin K, Smaldone M, Egleston BL, Higgins A, Winchester DP, Uzzo RG, Kutikov A.

BJU Int. 2017 Aug;120(2):239-245. doi: 10.1111/bju.13804. Epub 2017 Mar 10.

18.

Comparative Effectiveness and Risks of Bowel Preparation Before Elective Colorectal Surgery.

Koller SE, Bauer KW, Egleston BL, Smith R, Philp MM, Ross HM, Esnaola NF.

Ann Surg. 2018 Apr;267(4):734-742. doi: 10.1097/SLA.0000000000002159.

PMID:
28151800
19.

Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.

Franco-Barraza J, Francescone R, Luong T, Shah N, Madhani R, Cukierman G, Dulaimi E, Devarajan K, Egleston BL, Nicolas E, Katherine Alpaugh R, Malik R, Uzzo RG, Hoffman JP, Golemis EA, Cukierman E.

Elife. 2017 Jan 31;6. pii: e20600. doi: 10.7554/eLife.20600.

20.

Causes of death among cancer patients.

Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, Meyer JE.

Ann Oncol. 2017 Feb 1;28(2):400-407. doi: 10.1093/annonc/mdw604.

21.

Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.

Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ.

Breast Cancer Res Treat. 2016 Dec;160(3):573. doi: 10.1007/s10549-016-4023-5. No abstract available.

PMID:
27766452
22.

Multiple Chronic Conditions and Hospitalizations Among Recipients of Long-Term Services and Supports.

Van Cleave JH, Egleston BL, Abbott KM, Hirschman KB, Rao A, Naylor MD.

Nurs Res. 2016 Nov/Dec;65(6):425-434.

23.

Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.

Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ.

Breast Cancer Res Treat. 2016 Nov;160(1):153-162. Epub 2016 Sep 17. Erratum in: Breast Cancer Res Treat. 2016 Dec;160(3):573.

24.

For Health-Related Quality of Life and Other Longitudinal Data, Analysis Should Distinguish Between Truncation by Death and Data Missing Because of Nonresponse.

Kurland BF, Egleston BL.

J Clin Oncol. 2016 Dec 20;34(36):4449. doi: 10.1200/JCO.2016.69.1220. Epub 2016 Oct 31. No abstract available.

PMID:
27601541
25.

Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History.

Bradbury AR, Patrick-Miller L, Schwartz LA, Egleston BL, Henry-Moss D, Domchek SM, Daly MB, Tuchman L, Moore C, Rauch PK, Shorter R, Karpink K, Sands CB.

J Clin Oncol. 2016 Oct 1;34(28):3409-16. doi: 10.1200/JCO.2015.66.3450. Epub 2016 Aug 22.

26.

Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN.

J Oncol Pract. 2016 Jul;12(7):e755-64. doi: 10.1200/JOP.2016.011049. Epub 2016 Jun 21.

27.

The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer.

Zaorsky NG, Egleston BL, Horwitz EM, Dicker AP, Nguyen PL, Showalter TN, Den RB.

Am J Clin Oncol. 2016 Aug;39(4):321-6. doi: 10.1097/COC.0000000000000313.

PMID:
27322694
28.

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, Chikwem A, Andrianov G, Singh S, Borghaei H, Serebriiskii IG, Gibbons DL, Kurie JM, Golemis EA, Boumber Y.

Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6955-60. doi: 10.1073/pnas.1513616113. Epub 2016 Jun 6.

29.

A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.

Gaponova AV, Nikonova AS, Deneka A, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA.

Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068. Epub 2016 Jun 7.

30.

Reply to P. Blanchard et al.

Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Ridge JA.

J Clin Oncol. 2016 Jul 1;34(19):2318-9. doi: 10.1200/JCO.2016.67.2832. Epub 2016 Apr 25. No abstract available.

PMID:
27114603
31.

Time to Surgery and Breast Cancer Survival in the United States.

Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong YN, Patel SA, Boraas M, Chang EI, Topham NS, Egleston BL.

JAMA Oncol. 2016 Mar;2(3):330-9. doi: 10.1001/jamaoncol.2015.4508. Erratum in: JAMA Oncol. 2016 Sep 1;2(9):1244.

32.

Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States.

Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA.

J Clin Oncol. 2016 Jan 10;34(2):169-78. doi: 10.1200/JCO.2015.61.5906. Epub 2015 Nov 30.

33.

Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease.

Nikonova AS, Deneka AY, Eckman L, Kopp MC, Hensley HH, Egleston BL, Golemis EA.

Front Oncol. 2015 Oct 16;5:228. doi: 10.3389/fonc.2015.00228. eCollection 2015.

34.

Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.

Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB.

Oncotarget. 2015 Nov 24;6(37):39614-33. doi: 10.18632/oncotarget.5554.

35.

Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients.

Bleicher RJ, Ruth K, Sigurdson ER, Daly JM, Boraas M, Anderson PR, Egleston BL.

Cancer. 2016 Jan 1;122(1):42-9. doi: 10.1002/cncr.29726. Epub 2015 Oct 19.

36.

Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas.

Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Bodian DL, Vockley JG, Zhou Y, Handorf EA, Egleston BL, Andrake MD, Nicolas E, Serebriiskii IG, Yen TJ, Hall MJ, Golemis EA, Enders GH.

Gastroenterology. 2015 Dec;149(7):1872-1883.e9. doi: 10.1053/j.gastro.2015.08.052. Epub 2015 Sep 5.

37.

Characteristics of clinical trials that require participants to be fluent in English.

Egleston BL, Pedraza O, Wong YN, Dunbrack RL Jr, Griffin CL, Ross EA, Beck JR.

Clin Trials. 2015 Dec;12(6):618-26. doi: 10.1177/1740774515592881. Epub 2015 Jul 7.

38.

Adolescent endogenous sex hormones and breast density in early adulthood.

Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF.

Breast Cancer Res. 2015 Jun 4;17:77. doi: 10.1186/s13058-015-0581-4.

39.

Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing.

Bradbury AR, Patrick-Miller LJ, Egleston BL, DiGiovanni L, Brower J, Harris D, Stevens EM, Maxwell KN, Kulkarni A, Chavez T, Brandt A, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM.

Genet Med. 2016 Jan;18(1):25-33. doi: 10.1038/gim.2015.19. Epub 2015 Apr 2.

PMID:
25834950
40.

A Simple Method for Evaluating Within Sample Prognostic Balance Achieved by Published Comorbidity Summary Measures.

Egleston BL, Uzzo RG, Beck JR, Wong YN.

Health Serv Res. 2015 Aug;50(4):1179-94. doi: 10.1111/1475-6773.12276. Epub 2014 Dec 18.

41.

Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.

Smithline ZB, Nikonova AS, Hensley HH, Cai KQ, Egleston BL, Proia DA, Seeger-Nukpezah T, Golemis EA.

PLoS One. 2014 Dec 4;9(12):e114403. doi: 10.1371/journal.pone.0114403. eCollection 2014.

42.

Endogenous sex hormones and breast density in young women.

Jung S, Stanczyk FZ, Egleston BL, Snetselaar LG, Stevens VJ, Shepherd JA, Van Horn L, LeBlanc ES, Paris K, Klifa C, Dorgan JF.

Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):369-78. doi: 10.1158/1055-9965.EPI-14-0939. Epub 2014 Nov 4.

43.

Development of a communication protocol for telephone disclosure of genetic test results for cancer predisposition.

Patrick-Miller LJ, Egleston BL, Fetzer D, Forman A, Bealin L, Rybak C, Peterson C, Corbman M, Albarracin J, Stevens E, Daly MB, Bradbury AR.

JMIR Res Protoc. 2014 Oct 29;3(4):e49. doi: 10.2196/resprot.3337.

44.

Nedd9 restrains renal cystogenesis in Pkd1-/- mice.

Nikonova AS, Plotnikova OV, Serzhanova V, Efimov A, Bogush I, Cai KQ, Hensley HH, Egleston BL, Klein-Szanto A, Seeger-Nukpezah T, Golemis EA.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12859-64. doi: 10.1073/pnas.1405362111. Epub 2014 Aug 19.

45.

Atomic bomb survivor cataract surgery prevalence data are consistent with non-zero threshold dose--Comment on article by Nakashima et al. 2013.

Doss M, Egleston BL, Litwin S.

Health Phys. 2014 Sep;107(3):262-3. doi: 10.1097/HP.0000000000000137. No abstract available.

46.

Skin involvement and breast cancer: are T4b lesions of all sizes created equal?

Silverman D, Ruth K, Sigurdson ER, Egleston BL, Goldstein LJ, Wong YN, Boraas M, Bleicher RJ.

J Am Coll Surg. 2014 Sep;219(3):534-44. doi: 10.1016/j.jamcollsurg.2014.04.003. Epub 2014 Apr 20.

47.

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ.

Cell Cycle. 2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23.

48.

Psychological reactivity to laboratory stress is associated with hormonal responses in postmenopausal women.

Fang CY, Egleston BL, Manzur AM, Townsend RR, Stanczyk FZ, Spiegel D, Dorgan JF.

J Int Med Res. 2014 Apr;42(2):444-56. doi: 10.1177/0300060513504696. Epub 2014 Mar 4.

49.

Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care?

Loveland-Jones CE, Ruth K, Sigurdson ER, Egleston BL, Boraas M, Bleicher RJ.

Breast Cancer Res Treat. 2014 Feb;143(3):571-7. doi: 10.1007/s10549-014-2834-9. Epub 2014 Jan 19.

50.

Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database.

Canter DJ, Mallin K, Uzzo RG, Egleston BL, Simhan J, Walton J, Smaldone MC, Master VA, Bratslavsky G, Kutikov A.

Can J Urol. 2013 Oct;20(5):6915-21.

PMID:
24128829

Supplemental Content

Loading ...
Support Center